Advertisement Injectable Sustained Release Formulations of Therapeutic Proteins - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More

ARTES Biotechnology

Contract R&D Services and Patent Protected Expression Systems for Recombinant...

More info about ARTES Biotechnology

Injectable Sustained Release Formulations of Therapeutic Proteins

The study is designed to evaluate Q Chip’s Q-Sphera™ peptide and protein delivery platform to develop a new sustained release microsphere formulation composed of biocompatible polymers loaded with interferon alpha 2a manufactured from ARTES’ proprietary yeast Hansenula polymorpha expression system.
Q-SpheraTM is a highly enabling bio-encapsulation technology for the development of polymer based sustained release systems. No harsh solvents or manufacturing conditions are used in the production of drug (including peptides and proteins) loaded microspheres facilitating benign processing of labile molecules.

Hansenula based products, which are already marketed worldwide, are characterized by safety and cost efficiency superior to other microbial technologies. Interferon alpha 2a manufactured from Hansenula has proven to be better tolerated than the E. coli reference.

The collaboration aims to improve patient compliance and provide a more convenient dosing schedule compared with current marketed pegylated therapies through the development of a one month sustained release microsphere formulation. This first phase of the collaboration is expected to be completed by the end of 2010.